Drs. Svoboda, Rush, Grider, Prickett, and Phillips are from Virginia Tech Carilion School of Medicine, Roanoke. Drs. Rush, Grider, Prickett, and Phillips are from the Section of Dermatology, Department of Internal Medicine. Drs. Rush and Grider also are from the Department of Basic Science Education. Dr. Garofola is from the Department of Dermatology, LewisGale Hospital Montgomery, Blacksburg, Virginia.
Cutis. 2021 Jun;107(6):E5-E9. doi: 10.12788/cutis.0280.
Squamoid eccrine ductal carcinoma (SEDC) is a rare and under-recognized primary cutaneous tumor with a high risk for local recurrence and metastasis. The tumor has a biphasic histologic appearance consisting of a superficial portion indistinguishable from squamous cell carcinoma (SCC) and a deeper component demonstrating eccrine ductal differentiation. Because of superficial sampling, SEDC often is misdiagnosed as SCC during the initial biopsy. The diagnosis usually is made during complete excision when deeper tissue is sampled. Confirmation of the diagnosis can be achieved by immunohistochemical positivity for carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA), cytokeratin (CK) 5/6, and p63. In this article, we review the clinical and histologic details of 5 patients with SEDC who underwent successful treatment with Mohs micrographic surgery (MMS) at a single institution between November 2018 and May 2020. We also review the histologic patterns that helped distinguish SEDC from SCC upon complete excision. Our findings support the use of MMS as the treatment of choice for SEDC, given that all of the patients we reviewed required more than 1 Mohs stage for complete tumor clearance, and none demonstrated evidence of recurrence or metastasis after a mean follow-up period of 11 months.
鳞样汗腺导管癌(SEDC)是一种罕见且认识不足的原发性皮肤肿瘤,具有局部复发和转移的高风险。该肿瘤具有双相组织学表现,由与鳞状细胞癌(SCC)无法区分的浅表部分和显示汗管分化的深部成分组成。由于浅表取样,SEDC 在初次活检时常被误诊为 SCC。当对深部组织进行取样时,通常在完全切除时做出诊断。通过癌胚抗原(CEA)、上皮膜抗原(EMA)、细胞角蛋白(CK)5/6 和 p63 的免疫组织化学阳性可证实诊断。本文回顾了 2018 年 11 月至 2020 年 5 月在一家机构接受 Mohs 显微外科手术(MMS)成功治疗的 5 例 SEDC 患者的临床和组织学细节。我们还回顾了在完全切除时有助于将 SEDC 与 SCC 区分开来的组织学模式。我们的发现支持将 MMS 作为 SEDC 的治疗选择,因为我们回顾的所有患者都需要多个 Mohs 阶段才能完全清除肿瘤,且在平均 11 个月的随访期后均未显示复发或转移的证据。